BR112019000107A2 - composições e métodos com base em crispr / cas9 para o tratamento do câncer - Google Patents
composições e métodos com base em crispr / cas9 para o tratamento do câncerInfo
- Publication number
- BR112019000107A2 BR112019000107A2 BR112019000107-7A BR112019000107A BR112019000107A2 BR 112019000107 A2 BR112019000107 A2 BR 112019000107A2 BR 112019000107 A BR112019000107 A BR 112019000107A BR 112019000107 A2 BR112019000107 A2 BR 112019000107A2
- Authority
- BR
- Brazil
- Prior art keywords
- crispr
- methods
- raav
- cancer treatment
- based compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
a presente invenção refere-se aos métodos para prevenir, inibir ou tratar câncer em um indivíduo. são também fornecidos na presente invenção os métodos para alterar a expressão de um ou mais produtos do gene em uma célula, tal como uma célula do câncer. tais métodos podem compreender o uso de um sistema de nuclease modificado, tal como repetições palindrómicas curtas intercaladas regularmente interconectadas (crispr) / crispr associadas (cas)9 (crispr-cas9) compreendendo um promotor h1 bidirecional e grnas dirigidos a oncogenes (raav-onco-crispr) ou genes supressores de tumor (raav-tsg) empacotados em uma partícula compacta de vírus adenoassociado (aav). tais métodos podem compreender a coadministração ou simultaneamente fornecer um adenovírus de empacotamento de vírus adenoassociado recombinante (ad-raavpack) com o sistema de nuclease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662358339P | 2016-07-05 | 2016-07-05 | |
US62/358,339 | 2016-07-05 | ||
PCT/US2017/040696 WO2018009525A1 (en) | 2016-07-05 | 2017-07-05 | Crispr/cas9-based compositions and methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019000107A2 true BR112019000107A2 (pt) | 2019-04-09 |
Family
ID=60913122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019000107-7A BR112019000107A2 (pt) | 2016-07-05 | 2017-07-05 | composições e métodos com base em crispr / cas9 para o tratamento do câncer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200069818A1 (pt) |
EP (1) | EP3481431A4 (pt) |
JP (1) | JP2019520394A (pt) |
KR (1) | KR20190039115A (pt) |
CN (1) | CN109963598A (pt) |
AU (1) | AU2017292772A1 (pt) |
BR (1) | BR112019000107A2 (pt) |
CA (1) | CA3029908A1 (pt) |
CL (1) | CL2019000023A1 (pt) |
EA (1) | EA201990214A1 (pt) |
IL (1) | IL264034A (pt) |
MX (1) | MX2019000188A (pt) |
SG (1) | SG11201900028VA (pt) |
WO (1) | WO2018009525A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016016833A (es) * | 2014-06-16 | 2017-10-04 | Univ Johns Hopkins | Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1. |
US9855445B2 (en) | 2016-04-01 | 2018-01-02 | Varian Medical Systems, Inc. | Radiation therapy systems and methods for delivering doses to a target volume |
US11590364B2 (en) | 2017-07-21 | 2023-02-28 | Varian Medical Systems International Ag | Material inserts for radiation therapy |
US11712579B2 (en) | 2017-07-21 | 2023-08-01 | Varian Medical Systems, Inc. | Range compensators for radiation therapy |
US10843011B2 (en) | 2017-07-21 | 2020-11-24 | Varian Medical Systems, Inc. | Particle beam gun control systems and methods |
US10549117B2 (en) | 2017-07-21 | 2020-02-04 | Varian Medical Systems, Inc | Geometric aspects of radiation therapy planning and treatment |
US10092774B1 (en) | 2017-07-21 | 2018-10-09 | Varian Medical Systems International, AG | Dose aspects of radiation therapy planning and treatment |
EP3710111B1 (en) | 2017-11-16 | 2021-12-29 | Varian Medical Systems, Inc. | Increased beam output and dynamic field shaping for radiotherapy system |
CN108265116A (zh) * | 2018-01-22 | 2018-07-10 | 上海市第人民医院 | Klf4作为肝癌疾病诊断和治疗靶点 |
CA3092459A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
BR112020018620A2 (pt) * | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imunoterapia aprimorada |
CN112533627A (zh) * | 2018-03-27 | 2021-03-19 | G+Flas 生命科学公司 | 序列特异性体内细胞靶向 |
CN111989113A (zh) * | 2018-03-27 | 2020-11-24 | G+Flas生命科学有限公司 | 用于治疗癌症的包含向导rna和核酸内切酶作活性成分的药物组合物 |
US20210115449A1 (en) * | 2018-04-19 | 2021-04-22 | Board Of Regents, The University Of Texas System | Therapeutic modulation of tumor suppressors using exosomes |
CN108588194A (zh) * | 2018-05-28 | 2018-09-28 | 北京诺禾致源科技股份有限公司 | 利用高通量测序数据检测肿瘤突变负荷的方法及装置 |
US10910188B2 (en) | 2018-07-25 | 2021-02-02 | Varian Medical Systems, Inc. | Radiation anode target systems and methods |
WO2020022802A1 (ko) * | 2018-07-25 | 2020-01-30 | 주식회사 툴젠 | 인위적인 유전자 조작을 통한 자가면역질환 치료 |
AU2019341000B2 (en) * | 2018-09-12 | 2023-03-16 | Institute For Basic Science | Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition |
IT201800009431A1 (it) * | 2018-10-15 | 2020-04-15 | Universita' Degli Studi Di Siena | Sistema CRISPR-Cas per l’editing genomico. |
EP3640329A1 (en) * | 2018-10-18 | 2020-04-22 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Gene editing based cancer treatment |
US11116995B2 (en) | 2019-03-06 | 2021-09-14 | Varian Medical Systems, Inc. | Radiation treatment planning based on dose rate |
US10814144B2 (en) | 2019-03-06 | 2020-10-27 | Varian Medical Systems, Inc. | Radiation treatment based on dose rate |
US11103727B2 (en) | 2019-03-08 | 2021-08-31 | Varian Medical Systems International Ag | Model based PBS optimization for flash therapy treatment planning and oncology information system |
US11090508B2 (en) | 2019-03-08 | 2021-08-17 | Varian Medical Systems Particle Therapy Gmbh & Co. Kg | System and method for biological treatment planning and decision support |
CN109897854B (zh) * | 2019-03-28 | 2020-12-25 | 江苏浦珠生物医药科技有限公司 | 一种双sgRNA位点敲除ZYG11A基因的CRISPR/Cas9系统与应用 |
KR20220018504A (ko) | 2019-05-23 | 2022-02-15 | 크리스티아나 케어 헬스 서비시즈 인코포레이티드 | 암 치료를 위한 변이체 nrf2의 유전자 녹아웃 |
US10918886B2 (en) | 2019-06-10 | 2021-02-16 | Varian Medical Systems, Inc. | Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping |
US20220349893A1 (en) * | 2019-09-12 | 2022-11-03 | The Wistar Institute Of Anatomy And Biology | Methods for the treatment of arid1a-deficient cancers |
US11291859B2 (en) | 2019-10-03 | 2022-04-05 | Varian Medical Systems, Inc. | Radiation treatment planning for delivering high dose rates to spots in a target |
CN110772646A (zh) * | 2019-10-15 | 2020-02-11 | 天津大学 | 共载多烯紫杉醇与crispr/cas9脂质体及应用 |
KR102337860B1 (ko) * | 2019-11-05 | 2021-12-10 | 중앙대학교 산학협력단 | 슈와크만-보디안-다이아몬드 증후군 유전자의 발현 억제제를 유효성분으로 포함하는 유방암 치료제 효율 증진용 조성물 |
US20230096378A1 (en) * | 2020-03-12 | 2023-03-30 | Institute For Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
US11865361B2 (en) | 2020-04-03 | 2024-01-09 | Varian Medical Systems, Inc. | System and method for scanning pattern optimization for flash therapy treatment planning |
WO2021216503A1 (en) * | 2020-04-20 | 2021-10-28 | Christiana Care Health Services, Inc. | Aav delivery system for lung cancer treatment |
AU2021261423A1 (en) * | 2020-04-24 | 2022-12-08 | Aadigen, Llc | Compositions for treating cancer with KRAS mutations and uses thereof |
US11541252B2 (en) | 2020-06-23 | 2023-01-03 | Varian Medical Systems, Inc. | Defining dose rate for pencil beam scanning |
US11957934B2 (en) | 2020-07-01 | 2024-04-16 | Siemens Healthineers International Ag | Methods and systems using modeling of crystalline materials for spot placement for radiation therapy |
WO2023070108A1 (en) * | 2021-10-22 | 2023-04-27 | Spotlight Therapeutics | Guide rnas and uses thereof |
WO2023143474A1 (en) * | 2022-01-26 | 2023-08-03 | Anchordx Medical Co., Ltd. | Methods for treating gastric cancer |
WO2023205844A1 (en) * | 2022-04-26 | 2023-11-02 | Peter Maccallum Cancer Institute | Nucleic acids and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105441440B (zh) * | 2012-10-23 | 2020-12-15 | 基因工具股份有限公司 | 包含特异于靶dna的向导rna和cas蛋白质编码核酸或cas蛋白质的用于切割靶dna的组合物及其用途 |
CN105793425B (zh) * | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
US20150098954A1 (en) * | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
MX2016016833A (es) * | 2014-06-16 | 2017-10-04 | Univ Johns Hopkins | Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1. |
WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016054225A1 (en) * | 2014-09-30 | 2016-04-07 | Stc.Unm | Plasmid delivery in the treatment of cancer and other disease states |
JP6879910B2 (ja) * | 2014-10-31 | 2021-06-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Cart細胞における遺伝子発現の改変およびその使用 |
-
2017
- 2017-07-05 WO PCT/US2017/040696 patent/WO2018009525A1/en unknown
- 2017-07-05 US US16/315,468 patent/US20200069818A1/en not_active Abandoned
- 2017-07-05 AU AU2017292772A patent/AU2017292772A1/en not_active Abandoned
- 2017-07-05 CN CN201780054063.7A patent/CN109963598A/zh active Pending
- 2017-07-05 SG SG11201900028VA patent/SG11201900028VA/en unknown
- 2017-07-05 MX MX2019000188A patent/MX2019000188A/es unknown
- 2017-07-05 JP JP2019500338A patent/JP2019520394A/ja active Pending
- 2017-07-05 EP EP17824792.0A patent/EP3481431A4/en not_active Withdrawn
- 2017-07-05 EA EA201990214A patent/EA201990214A1/ru unknown
- 2017-07-05 CA CA3029908A patent/CA3029908A1/en not_active Abandoned
- 2017-07-05 BR BR112019000107-7A patent/BR112019000107A2/pt not_active Application Discontinuation
- 2017-07-05 KR KR1020197003437A patent/KR20190039115A/ko unknown
-
2018
- 2018-12-31 IL IL264034A patent/IL264034A/en unknown
-
2019
- 2019-01-04 CL CL2019000023A patent/CL2019000023A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2019000023A1 (es) | 2019-06-21 |
AU2017292772A1 (en) | 2019-02-21 |
JP2019520394A (ja) | 2019-07-18 |
EP3481431A4 (en) | 2020-01-01 |
WO2018009525A8 (en) | 2019-02-07 |
MX2019000188A (es) | 2019-06-20 |
SG11201900028VA (en) | 2019-01-30 |
KR20190039115A (ko) | 2019-04-10 |
EP3481431A1 (en) | 2019-05-15 |
CN109963598A (zh) | 2019-07-02 |
IL264034A (en) | 2019-01-31 |
US20200069818A1 (en) | 2020-03-05 |
WO2018009525A1 (en) | 2018-01-11 |
CA3029908A1 (en) | 2018-01-11 |
EA201990214A1 (ru) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019000107A2 (pt) | composições e métodos com base em crispr / cas9 para o tratamento do câncer | |
BR112019000057A2 (pt) | composições e métodos com base em crispr/cas9 para o tratamento de degeneração de retina | |
BR112016028023A2 (pt) | Composições e métodos de administração de tratamentos para infecções virais latentes | |
BR112019009113A2 (pt) | formulações de vírus adenoassociado | |
WO2016137235A3 (ko) | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 | |
BR112019007346A2 (pt) | plasmídeo com conjunto de circuitos cas9 autolimitantes para segurança realçada (slices) e sistema lentiviral do mesmo | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
PH12017502192A1 (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
CL2022001719A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
BR112015021884A8 (pt) | vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica | |
WO2016154127A3 (en) | Compositions and methods for treating hypertriglyceridemia | |
MX2017007321A (es) | Terapias de combinacion. | |
BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2015012056A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
BR112015024621A8 (pt) | usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi | |
MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
BR112017019358A2 (pt) | combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |